US 12,285,426 B2
Combination serotonin specific reuptake inhibitor and serotonin 1A receptor partial agonist for reducing L-DOPA-induced dyskinesia
Christopher Roy Bishop, Vestal, NY (US); Anthony West, North Chicago, IL (US); and Fredric Manfredsson, Grand Rapids, MI (US)
Assigned to The Research Foundation for The State University of New York, Binghamton, NY (US); Rosalind Franklin University of Medicine and Science, North Chicago, IL (US); and Board of Trustees of Michigan State University, East Lansing, MI (US)
Filed by The Research Foundation for The State University of new York, Binghamton, NY (US); Rosalind Franklin University of Medicine and Science, North Chicago, IL (US); and Board of Trustees of Michigan State University, East Lansing, MI (US)
Filed on Apr. 26, 2021, as Appl. No. 17/240,969.
Application 17/240,969 is a continuation in part of application No. PCT/US2019/058199, filed on Oct. 25, 2019.
Claims priority of provisional application 62/751,247, filed on Oct. 26, 2018.
Prior Publication US 2021/0346372 A1, Nov. 11, 2021
Int. Cl. A61K 31/496 (2006.01); A61K 9/00 (2006.01); A61K 31/05 (2006.01); A61K 31/13 (2006.01); A61K 31/198 (2006.01); A61K 31/4545 (2006.01); A61K 31/495 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01); A61P 25/16 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 9/0053 (2013.01); A61K 31/05 (2013.01); A61K 31/13 (2013.01); A61K 31/198 (2013.01); A61K 31/4545 (2013.01); A61K 31/495 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); A61P 25/16 (2018.01)] 16 Claims
 
1. A pharmaceutically-acceptable oral unit dose, for treating or reducing risk of L-DOPA induced dyskinesia in a human patient having Parkinson's Disease, comprising:
at least one of agent selected from the group consisting of vilazodone and vortioxetine, in a sufficient amount to treat the L-DOPA induced dyskinesia of the human patient; and
at least one second agent selected from the group consisting of:
DOPA decarboxylase inhibitor in an effective amount to reduce peripheral decarboxylation of L-DOPA,
a catechol-O-methyl transferase inhibitor,
a monoamine oxidase type B inhibitor,
a dopamine receptor agonist,
an anticholinergic agent,
an antimuscarinic agent, and
a cannabinoid.